Viral infections:
Indications for: EMTRIVA
HIV-1 infection, in combination with other antiretroviral agents.
Adult Dosage:
≥18yrs: 200mg once daily. Renal impairment (CrCl 30–49mL/min): 200mg every 48hrs; (CrCl 15–29mL/min): 200mg every 72hrs; (CrCl <15mL/min or dialysis): 200mg every 96hrs.
Children Dosage:
<3mos: use oral soln. 3mos–17yrs (≤33kg): use oral soln; (>33kg): 200mg once daily. Renal impairment: reduce dose or prolong dosing interval (see full labeling).
Boxed Warning:
Posttreatment exacerbation of hepatitis B.
EMTRIVA Warnings/Precautions:
Not for treating chronic HBV infection; test for HBV before starting therapy and closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. Suspend therapy if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Renal impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.
See Also:
EMTRIVA Classification:
Nucleoside analogue (reverse transcriptase inhibitor).
EMTRIVA Interactions:
Avoid concomitant drugs that contain emtricitabine or lamivudine (eg, fixed dose combination products).
Adverse Reactions:
Headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, rhinitis; new onset or worsening renal impairment, immune reconstitution syndrome; also children: skin hyperpigmentation.
Note:
Register pregnant patients exposed to emtricitabine by calling (800) 258-4263.
How Supplied:
Caps—30; Soln—170mL
